10 Best Undervalued Stocks Insiders Are Buying for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The 2025 market landscape is shaped by persistent macroeconomic uncertainty, sector rotation, and a renewed focus on company fundamentals. At ValueSense, our stock selection methodology leverages a blend of quantitative metrics—such as intrinsic value, free cash flow, and return on invested capital (ROIC)—and qualitative insights derived from AI-powered earnings analysis[1][2]. Our watchlist prioritizes companies with strong value signals, robust financial health, and clear growth catalysts, while maintaining sector diversification to manage risk.
Featured Stock Analysis
Stock #1: Uber Technologies, Inc. (UBER)
| Metric | Value |
|---|---|
| Market Cap | $201.9B |
| Quality Rating | 7.5 |
| Intrinsic Value | $201.7 |
| 1Y Return | 33.9% |
| Revenue | $47.3B |
| Free Cash Flow | $8,540.0M |
| Revenue Growth | 18.2% |
| FCF margin | 18.0% |
| Gross margin | 39.7% |
| ROIC | 66.4% |
| Total Debt to Equity | 52.2% |
Investment Thesis
Uber stands out as a leading platform in the global mobility and delivery markets, with a market cap of $201.9B. The company’s robust revenue of $47.3B and impressive free cash flow of $8.54B underscore its operational efficiency. Uber’s 18.2% revenue growth and a high ROIC of 66.4% highlight its ability to convert capital into profits efficiently. The intrinsic value estimate of $201.7 suggests the stock is trading near its fair value, supported by a solid quality rating of 7.5.
Uber’s business model benefits from network effects and scale, positioning it to capitalize on urbanization trends and the shift toward app-based transportation and logistics. Its 1-year return of 33.9% reflects strong market confidence in its growth trajectory.
Key Catalysts
- Expansion of delivery and logistics services beyond ride-hailing
- Continued urban mobility adoption and international growth
- Margin improvement through operational leverage and technology integration
- Potential new business lines (e.g., autonomous vehicles, freight)
Risk Factors
- Regulatory pressures in key markets
- Competitive threats from both traditional and tech-driven rivals
- Sensitivity to fuel prices and macroeconomic cycles
- Execution risk in scaling new business segments
Stock #2: Intel Corporation (INTC)
| Metric | Value |
|---|---|
| Market Cap | $180.5B |
| Quality Rating | 5.1 |
| Intrinsic Value | $74.5 |
| 1Y Return | 85.8% |
| Revenue | $53.4B |
| Free Cash Flow | ($7,251.0M) |
| Revenue Growth | (1.5%) |
| FCF margin | (13.6%) |
| Gross margin | 35.8% |
| ROIC | (1.3%) |
| Total Debt to Equity | 39.9% |
Investment Thesis
Intel, with a $180.5B market cap, remains a foundational player in the global semiconductor industry. Despite a challenging year with a 1.5% revenue decline and negative free cash flow of $7.25B, Intel’s 1-year return of 85.8% signals renewed investor optimism. The company’s intrinsic value of $74.5 and a quality rating of 5.1 indicate a moderate value proposition, especially as Intel pivots toward advanced manufacturing and AI-driven chip design.
Intel’s strategic investments in foundry services and next-generation process nodes aim to reclaim technological leadership. Its gross margin of 35.8% and manageable total debt to equity of 39.9% provide a foundation for recovery as cyclical headwinds abate.
Key Catalysts
- Ramp-up of new fabrication facilities and process technologies
- AI and data center chip demand growth
- Strategic partnerships and government incentives for domestic chip production
- Potential for margin recovery as supply chain normalizes
Risk Factors
- Execution risk in manufacturing transitions
- Intense competition from AMD, NVIDIA, and Asian foundries
- Cyclical demand swings in PC and server markets
- Ongoing negative free cash flow and ROIC -1.3%
Stock #3: The Boeing Company (BA)
| Metric | Value |
|---|---|
| Market Cap | $152.1B |
| Quality Rating | 4.8 |
| Intrinsic Value | $231.4 |
| 1Y Return | 34.6% |
| Revenue | $80.8B |
| Free Cash Flow | ($4,364.0M) |
| Revenue Growth | 10.2% |
| FCF margin | (5.4%) |
| Gross margin | 1.1% |
| ROIC | (7.9%) |
| Total Debt to Equity | (646.5%) |
Investment Thesis
Boeing, with a $152.1B market cap, is a global aerospace leader navigating a complex recovery. The company’s $80.8B in revenue and 10.2% revenue growth reflect a rebound in commercial aviation demand. However, negative free cash flow $4.36B, a low gross margin 1.1%, and a high total debt to equity ratio -646.5% highlight ongoing financial challenges. The intrinsic value of $231.4 suggests significant upside if operational issues are resolved.
Boeing’s long-term prospects are tied to global air travel recovery, defense contracts, and successful execution of its aircraft delivery backlog. The 1-year return of 34.6% indicates market belief in a turnaround.
Key Catalysts
- Resumption of 737 MAX and 787 deliveries
- Growth in defense and space contracts
- Global fleet replacement cycle post-pandemic
- Cost-cutting and operational restructuring
Risk Factors
- High leverage and negative ROIC -7.9%
- Supply chain disruptions and regulatory scrutiny
- Execution risk in ramping up production
- Sensitivity to macroeconomic and geopolitical shocks
Stock #4: Pfizer Inc. (PFE)
| Metric | Value |
|---|---|
| Market Cap | $140.1B |
| Quality Rating | 6.3 |
| Intrinsic Value | $39.3 |
| 1Y Return | -10.1% |
| Revenue | $63.8B |
| Free Cash Flow | $12.4B |
| Revenue Growth | 14.7% |
| FCF margin | 19.5% |
| Gross margin | 66.2% |
| ROIC | 10.6% |
| Total Debt to Equity | 69.4% |
Investment Thesis
Pfizer, with a $140.1B market cap, is a pharmaceutical giant with a strong track record in drug development and commercialization. The company’s $63.8B in revenue, 14.7% revenue growth, and robust free cash flow $12.4B support its intrinsic value estimate of $39.3. Pfizer’s high gross margin 66.2% and ROIC 10.6% reflect efficient operations, while a quality rating of 6.3 signals solid fundamentals.
Despite a -10.1% 1-year return, Pfizer’s pipeline and global reach position it to benefit from ongoing healthcare innovation and demographic trends.
Key Catalysts
- New drug launches and pipeline progress
- Expansion in emerging markets
- Strategic acquisitions and partnerships
- Cost management and margin expansion
Risk Factors
- Patent expirations and generic competition
- Regulatory and pricing pressures
- Dependence on blockbuster drugs
- Market volatility in healthcare sector
Stock #5: Medtronic plc (MDT)
| Metric | Value |
|---|---|
| Market Cap | $116.2B |
| Quality Rating | 6.7 |
| Intrinsic Value | $120.6 |
| 1Y Return | 2.5% |
| Revenue | $34.2B |
| Free Cash Flow | $5,303.0M |
| Revenue Growth | 5.0% |
| FCF margin | 15.5% |
| Gross margin | 63.4% |
| ROIC | 8.2% |
| Total Debt to Equity | 59.4% |
Investment Thesis
Medtronic, valued at $116.2B, is a leading medical device innovator. The company’s $34.2B in revenue, 5.0% revenue growth, and $5.3B in free cash flow underpin its intrinsic value of $120.6. Medtronic’s high gross margin 63.4% and ROIC 8.2% support its quality rating of 6.7, reflecting operational excellence and a diversified product portfolio.
Medtronic’s focus on minimally invasive therapies and global expansion positions it for steady growth, with a modest 1-year return of 2.5% indicating stability.
Key Catalysts
- Launch of next-generation medical devices
- Expansion in emerging healthcare markets
- Strategic M&A to enhance product pipeline
- Operational efficiency initiatives
Risk Factors
- Regulatory hurdles for new devices
- Pricing pressures from healthcare systems
- Currency fluctuations impacting global sales
- Competition from other medtech firms
Stock #6: ConocoPhillips (COP)
| Metric | Value |
|---|---|
| Market Cap | $111.7B |
| Quality Rating | 5.9 |
| Intrinsic Value | $113.5 |
| 1Y Return | -17.6% |
| Revenue | $58.3B |
| Free Cash Flow | $6,923.0M |
| Revenue Growth | 3.5% |
| FCF margin | 11.9% |
| Gross margin | 28.7% |
| ROIC | 9.3% |
| Total Debt to Equity | 35.9% |
Investment Thesis
ConocoPhillips, with a $111.7B market cap, is a major player in the energy sector. The company’s $58.3B in revenue, positive free cash flow $6.92B, and 3.5% revenue growth highlight its resilience amid commodity price volatility. The intrinsic value of $113.5 and a quality rating of 5.9 suggest moderate upside potential.
ConocoPhillips benefits from a diversified asset base and disciplined capital allocation, with an 11.9% FCF margin and 9.3% ROIC supporting long-term value creation. The -17.6% 1-year return reflects recent sector headwinds.
Key Catalysts
- Oil price recovery and production growth
- Portfolio optimization and asset sales
- Shareholder returns via dividends and buybacks
- Energy transition initiatives
Risk Factors
- Commodity price volatility
- Regulatory and environmental risks
- Capital-intensive operations
- Geopolitical tensions affecting supply chains
Stock #7: Enbridge Inc. (ENB)
| Metric | Value |
|---|---|
| Market Cap | $101.6B |
| Quality Rating | 5.4 |
| Intrinsic Value | $75.2 |
| 1Y Return | 18.9% |
| Revenue | CA$64.5B |
| Free Cash Flow | CA$4,631.0M |
| Revenue Growth | 48.5% |
| FCF margin | 7.2% |
| Gross margin | 32.6% |
| ROIC | 5.1% |
| Total Debt to Equity | 147.8% |
Investment Thesis
Enbridge, with a $101.6B market cap, is a leading North American energy infrastructure company. The company’s CA$64.5B in revenue, 48.5% revenue growth, and CA$4.63B in free cash flow highlight its scale and stability. Enbridge’s intrinsic value of $75.2 and a quality rating of 5.4 indicate a balanced risk-reward profile.
Enbridge’s extensive pipeline network and regulated assets provide predictable cash flows, supporting an 18.9% 1-year return and a 7.2% FCF margin.
Key Catalysts
- Expansion of pipeline and utility infrastructure
- Renewable energy investments
- Stable cash flows from regulated assets
- Strategic acquisitions
Risk Factors
- High leverage (total debt to equity 147.8%)
- Regulatory and environmental scrutiny
- Commodity price exposure
- Project execution risks
Stock #8: United Parcel Service, Inc. (UPS)
| Metric | Value |
|---|---|
| Market Cap | $81.9B |
| Quality Rating | 6.0 |
| Intrinsic Value | $138.0 |
| 1Y Return | -26.1% |
| Revenue | $89.4B |
| Free Cash Flow | $4,396.0M |
| Revenue Growth | (1.3%) |
| FCF margin | 4.9% |
| Gross margin | 18.1% |
| ROIC | 12.6% |
| Total Debt to Equity | 184.3% |
Investment Thesis
UPS, with an $81.9B market cap, is a global logistics leader. The company’s $89.4B in revenue, 4.9% FCF margin, and $4.4B in free cash flow demonstrate operational strength. Despite a -26.1% 1-year return and a 1.3% revenue decline, UPS’s intrinsic value of $138.0 and a quality rating of 6.0 suggest potential for recovery as global trade rebounds.
UPS’s scale, technology investments, and diversified service offerings position it to benefit from e-commerce growth and supply chain optimization.
Key Catalysts
- E-commerce and last-mile delivery growth
- Automation and digital transformation
- Expansion in healthcare logistics
- Cost management initiatives
Risk Factors
- Cyclical demand and economic sensitivity
- Labor costs and union negotiations
- Competitive pressures from FedEx, Amazon, and regional players
- High leverage (total debt to equity 184.3%)
Stock #9: Elevance Health Inc. (ELV)
| Metric | Value |
|---|---|
| Market Cap | $71.6B |
| Quality Rating | 6.1 |
| Intrinsic Value | $295.5 |
| 1Y Return | -21.2% |
| Revenue | $194.8B |
| Free Cash Flow | $3,767.0M |
| Revenue Growth | 12.0% |
| FCF margin | 1.9% |
| Gross margin | 77.7% |
| ROIC | 14.7% |
| Total Debt to Equity | 2.1% |
Investment Thesis
Elevance Health, with a $71.6B market cap, is a major U.S. health insurer. The company’s $194.8B in revenue, 12.0% revenue growth, and $3.77B in free cash flow support its intrinsic value of $295.5. A quality rating of 6.1 and a high gross margin 77.7% reflect operational efficiency, though the 1-year return of -21.2% suggests recent sector challenges.
Elevance’s scale, diversified product offerings, and focus on managed care position it for long-term growth as healthcare spending rises.
Key Catalysts
- Growth in Medicare Advantage and Medicaid
- Digital health and care management initiatives
- Cost containment and efficiency gains
- Expansion into ancillary health services
Risk Factors
- Regulatory and reimbursement risks
- Competitive pressures in insurance markets
- Medical cost inflation
- Low FCF margin 1.9% and sensitivity to policy changes
Stock #10: CSX Corporation (CSX)
| Metric | Value |
|---|---|
| Market Cap | $67.1B |
| Quality Rating | 6.4 |
| Intrinsic Value | $37.5 |
| 1Y Return | 7.9% |
| Revenue | $15.0B |
| Free Cash Flow | $3,777.0M |
| Revenue Growth | 2.1% |
| FCF margin | 25.2% |
| Gross margin | 36.6% |
| ROIC | 18.8% |
| Total Debt to Equity | 12.3% |
Investment Thesis
CSX, with a $67.1B market cap, is a leading North American rail operator. The company’s $15.0B in revenue, 2.1% revenue growth, and $3.78B in free cash flow support its intrinsic value of $37.5. CSX’s high FCF margin 25.2%, gross margin 36.6%, and ROIC 18.8% highlight operational excellence, while a quality rating of 6.4 signals strong fundamentals.
CSX benefits from secular trends in freight transportation, infrastructure investment, and supply chain optimization. The 1-year return of 7.9% reflects steady performance.
Key Catalysts
- Infrastructure spending and freight demand growth
- Efficiency gains from technology adoption
- Expansion into intermodal and logistics services
- Shareholder returns via dividends and buybacks
Risk Factors
- Economic sensitivity and cyclical demand
- Regulatory and environmental compliance costs
- Competition from trucking and other railroads
- Exposure to fuel price volatility
Portfolio Diversification Insights
This watchlist spans technology, healthcare, industrials, energy, and logistics, providing broad sector diversification. Exposure to both growth and value stocks helps balance risk, while the inclusion of defensive sectors (healthcare, utilities) and cyclical names (industrials, energy) creates a resilient portfolio structure. Cross-sector allocation reduces the impact of sector-specific downturns and enhances long-term return potential.
Market Timing & Entry Strategies
While market timing is inherently challenging, dollar-cost averaging and phased entry can help mitigate volatility. Investors may consider entering positions during pullbacks or after earnings releases, when valuations are more attractive. Monitoring macroeconomic indicators, sector rotation trends, and company-specific catalysts can further refine entry points. ValueSense’s intrinsic value tools and backtesting features support disciplined, data-driven entry strategies[1][2].
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary blend of intrinsic value analysis, quality ratings, and financial health metrics, ensuring a focus on undervalued opportunities with strong fundamentals[1][2].
Q2: What's the best stock from this list?
Each stock offers unique strengths; the “best” depends on individual investment goals and risk tolerance. Uber and Intel show strong recent returns, while Pfizer and CSX provide defensive characteristics.
Q3: Should I buy all these stocks or diversify?
Diversification across sectors and business models helps manage risk. This watchlist is designed to offer a balanced mix, but allocation should align with your personal investment strategy.
Q4: What are the biggest risks with these picks?
Risks include sector-specific headwinds, regulatory changes, execution challenges, and macroeconomic volatility. Each stock’s risk profile is detailed in its analysis section.
Q5: When is the best time to invest in these stocks?
Optimal timing varies by stock and market conditions. Consider phased entry, monitor key catalysts, and use ValueSense’s intrinsic value and backtesting tools to inform your decisions[1][2].